找回密码
 To register

QQ登录

只需一步,快速开始

扫一扫,访问微社区

Titlebook: Congenital Bleeding Disorders; Diagnosis and Manage Akbar Dorgalaleh Book 2023Latest edition The Editor(s) (if applicable) and The Author(s

[复制链接]
查看: 38849|回复: 55
发表于 2025-3-21 17:35:21 | 显示全部楼层 |阅读模式
书目名称Congenital Bleeding Disorders
副标题Diagnosis and Manage
编辑Akbar Dorgalaleh
视频video
概述Offers detailed assistance in the diagnosis and management of bleeding disorders.Includes extensive coverage of rare disorders and the challenges that they pose.Provides up-to-date guidance on use of
图书封面Titlebook: Congenital Bleeding Disorders; Diagnosis and Manage Akbar Dorgalaleh Book 2023Latest edition The Editor(s) (if applicable) and The Author(s
描述This significantly updated new edition describes in detail the clinical presentations, diagnosis, and management of a wide range of congenital bleeding disorders. It will assist readers in overcoming the significant challenges involved in clinical and laboratory diagnosis and in providing effective clinical care that makes optimal use of new products, including recombinant factor concentrate. The coverage ranges from hemophilia A and B and von Willebrand disease to rare bleeding disorders such as congenital factor V, factor X, factor XI, and factor XIII deficiency and inherited platelet function disorders. The exceptional attention to rarer conditions is of particular importance given the considerable risk of overlooking them during diagnosis, with potential consequences for disease-related morbidity and mortality. The authors are acknowledged specialists in the field from across the world who have particular expertise in the disorder that they discuss. The book will be of value to hematologists, oncologists, pediatricians, laboratory specialists and technicians, general physicians, and trainees..
出版日期Book 2023Latest edition
关键词Common Bleeding Disorders; Von Willebrand Disorders; Hemophilia A; Hemophilia B; Rare Bleeding Disorders
版次2
doihttps://doi.org/10.1007/978-3-031-43156-2
isbn_softcover978-3-031-43158-6
isbn_ebook978-3-031-43156-2
copyrightThe Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerl
The information of publication is updating

书目名称Congenital Bleeding Disorders影响因子(影响力)




书目名称Congenital Bleeding Disorders影响因子(影响力)学科排名




书目名称Congenital Bleeding Disorders网络公开度




书目名称Congenital Bleeding Disorders网络公开度学科排名




书目名称Congenital Bleeding Disorders被引频次




书目名称Congenital Bleeding Disorders被引频次学科排名




书目名称Congenital Bleeding Disorders年度引用




书目名称Congenital Bleeding Disorders年度引用学科排名




书目名称Congenital Bleeding Disorders读者反馈




书目名称Congenital Bleeding Disorders读者反馈学科排名




单选投票, 共有 1 人参与投票
 

1票 100.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

0票 0.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用户组没有投票权限
发表于 2025-3-21 21:57:58 | 显示全部楼层
Merete Christiansen,Carsten K. Hansenessment. On-demand therapy is the mainstay of treatment in VWD, although long-term prophylaxis is emerging for those with recurrent and severe bleeding. Therapeutic choices in VWD depend to some extent on geographical location, but include VWF/FVIII concentrates, recombinant VWF, and desmopressin.
发表于 2025-3-22 03:36:51 | 显示全部楼层
发表于 2025-3-22 08:08:26 | 显示全部楼层
Christer Jönsson,Jonas Tallbergsma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.
发表于 2025-3-22 11:19:41 | 显示全部楼层
https://doi.org/10.1007/978-3-030-60679-4aterial positive (CRM+). Different therapeutic choices are available, including fresh frozen plasma and FXI concentrate. However, plasma and factor XI concentrates can provoke inhibitor formation. Recombinant FVIIa treatment can be used for such patients.
发表于 2025-3-22 15:23:14 | 显示全部楼层
von Willebrand Disease: An Update on Diagnosis and Treatmentessment. On-demand therapy is the mainstay of treatment in VWD, although long-term prophylaxis is emerging for those with recurrent and severe bleeding. Therapeutic choices in VWD depend to some extent on geographical location, but include VWF/FVIII concentrates, recombinant VWF, and desmopressin.
发表于 2025-3-22 20:41:56 | 显示全部楼层
发表于 2025-3-22 21:30:01 | 显示全部楼层
Congenital Factor VII Deficiency, Diagnosis, and Managementsma (FFP), plasma-derived FVII (pd-FVII), prothrombin complex concentrate (PCC), activated PCC (aPCC), and more recently, recombinant activated FVII (rFVIIa) are available for treatment of patients with FVII deficiency. New therapeutic options significantly improved the quality of life in patients with congenital FVII deficiency.
发表于 2025-3-23 01:59:21 | 显示全部楼层
发表于 2025-3-23 08:21:27 | 显示全部楼层
 关于派博传思  派博传思旗下网站  友情链接
派博传思介绍 公司地理位置 论文服务流程 影响因子官网 SITEMAP 大讲堂 北京大学 Oxford Uni. Harvard Uni.
发展历史沿革 期刊点评 投稿经验总结 SCIENCEGARD IMPACTFACTOR 派博系数 清华大学 Yale Uni. Stanford Uni.
|Archiver|手机版|小黑屋| 派博传思国际 ( 京公网安备110108008328) GMT+8, 2025-7-6 12:22
Copyright © 2001-2015 派博传思   京公网安备110108008328 版权所有 All rights reserved
快速回复 返回顶部 返回列表